Moderna’s Bird Flu Vaccine Contract Cancelled by Trump Admin

Due to recent discoveries about the potential dangers of mRNA vaccines which the bird flu vaccine has in it, the Trump administration is reportedly considering scrapping a $590 million contract awarded to Moderna for the development of an mRNA-based H5N1 bird flu vaccine.

The Backstory: Moderna’s Bird Flu Vaccine Deal

In July 2024, Moderna received a $176 million contract from the U.S. government to develop a vaccine targeting the H5N1 avian influenza strain, prompted by concerns over a handful of human cases and outbreaks among livestock. This initial funding was later expanded to $590 million, a move that some critics labeled as a last-minute push by the outgoing Biden administration to secure pandemic-related initiatives.

The vaccine, based on Moderna’s mRNA technology, was seen as a proactive step to address a potential public health threat, especially given the global attention on bird flu following reports of infections in both animals and humans. But many question the motives on this.

Numerous organic and regenerative farmers use natural herbs and pasture raising techniques to strengthen immunity in their chickens the way mother nature intended. They argue that manmade drugs and vaccines are not studied on humans long enough to see if the side effects are worth the risk. Tried and true natural remedies the Earth provides for free is often the best choice.

The narrative around mRNA vaccines, like Moderna’s proposed H5N1 bird flu vaccine, often ignores potential health risks that fuel public skepticism. Critics argue these vaccines, which use synthetic mRNA to instruct cells to produce viral proteins, may trigger unintended immune responses, including inflammation or rare side effects like myocarditis, as seen in some COVID-19 vaccine studies.

Long-term safety data remains limited, amplifying concerns about their rushed deployment for diseases like bird flu, which some claim is overhyped.

The "bird flu hoax" theory, circulating on social media that H5N1’s threat is exaggerated by governments and pharma companies to justify lucrative contracts for big bucks and more public health control measures, pointing to its low human transmission rate—only three U.S. cases in 2024—and minimal evidence of a looming pandemic.

While these claims are scrutinized by some, they reflect distrust in institutional motives, especially when contracts like Moderna’s $590 million deal emerge under questionable timing.

What’s Next?

As of now, no final decision has been made, and the Trump administration’s review is ongoing. If the contract is canceled, it could reshape Moderna’s role in U.S. pandemic preparedness and signal a broader pivot in how the government approaches vaccine development. For now, the public health community and investors alike are watching closely, with some expressing concern about the implications for future outbreaks, while others see the review as a necessary check on spending.

Our Final Thoughts

The debate over Moderna’s bird flu vaccine contract highlights the complex interplay of science, policy, and public perception.

As always, it’s worth digging beyond the headlines—whether on The Kennedy Journal or elsewhere—and questioning both the motives, financial and political, and substantial evidence behind such moves.